Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2026 | $24.00 | Equal Weight | Barclays |
| 1/21/2026 | $28.00 | Neutral → Buy | BofA Securities |
| 11/6/2025 | Peer Perform | Wolfe Research | |
| 10/15/2025 | $32.00 | Overweight | Wells Fargo |
| 9/26/2025 | $18.00 | Neutral → Sell | Goldman |
| 5/9/2025 | $23.00 | Buy → Neutral | BofA Securities |
| 5/9/2025 | $52.00 | Strong Buy → Outperform | Raymond James |
| 4/29/2025 | $44.00 | Overweight | Cantor Fitzgerald |
Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitabilityManagement to host conference call today at 8:30 a.m. ET WALTHAM, Mass., Feb. 24, 2026 (G
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET. The live conference webcast will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for approximately 30 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases p
Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that eight abstracts were accepted for oral presentations at the 49th Macula Society Annual Meeting, taking place February 25-28 in San Diego, California. New data to be presented include the comprehensive analysis from the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the most prescribed treatment for geographic atrophy (GA) secondary to age-related macular degenerati
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
S-8 - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
10-K - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
Barclays initiated coverage of Apellis Pharmaceuticals with a rating of Equal Weight and set a new price target of $24.00
BofA Securities upgraded Apellis Pharmaceuticals from Neutral to Buy and set a new price target of $28.00
Wolfe Research initiated coverage of Apellis Pharmaceuticals with a rating of Peer Perform
Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity
NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. "We are thrilled to welcome Craig to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Craig is a seasoned leader, who has successfully grown biopharmaceutical companies into strong commercial organizations with robust pipelines
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted
Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitabilityManagement to host conference call today at 8:30 a.m. ET WALTHAM, Mass., Feb. 24, 2026 (G
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 30 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company
Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary IC-MPGNReported EMPAVELI U.S. net product revenue of $27 million, reflecting strong early launch in C3G and primary IC-MPGN and continued high patient compliance in PNHSYFOVRE® (pegcetacoplan injection) total injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $151 millionCash and cash equivalents of $479 million as of September 30, 2025; existing cash expected to be sufficient to fund business to sustainable profitabilityManagement to host conference c
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)